Open Access
Research Article

Table 4

Features of children who recovered from persistent early-appearing anaemia and who subsequently progressed to late-appearing anaemia.

Patient (gender, age) Parasitaemia (μL−1) Pre-treatment HCT (%) Antimalarial treatment PRRD2 PCT (days) Nadir HCT at PEAA (%)b,c Anaemia recovery time (day) Time to LAA (day)d Nadir HCT at LAA (%)b,c HCT on day 42 (%) Time between recovery and LAA (day)
AD57 (M, 24m) 53,678 36 DHP 53,678 2 25 33 42 27 27 7
AD67 (F, 38m) 23,670 30 AA 23,670 1 26 13 35 26 30 21
IM/E/47 (F, 59m) 4846 30 AA 4846 2 26 20 35 28 28 14
IM/E/50 (F, 14m) 151,733 30 AA 151,733 2 25 20 42 25 25 21
IM/E/66 (F, 59m) 27,965 30 AL 27,965 1 26 13 21 28 28 7
KN/EN/90 (F, 24m) 30,166 30 DHP 30,166 1 23 13 35 29 38 21
KW10 (F, 42m) 120,050 34 AL 5002 3 23 20 28 29 32 7
SK18 (M, 16m) 4842 33 AL 4842 2 26 13 35 25 26 21
SK31 (F, 27m) 8538 31 AL 94.87 3 20 13 28 20 25 14
SK46 (F, 19m) 2004 31 AA 11.93 3 24 19 28 23 7
Mean (95% CI) 19,473 a 31.5 (30–33) 5413 a 1.8 (1.3–2.5) 24.4 (23–25.8) 16.9 (13.5–21.1) 32.3 (27.7–37.6) 26 (23.9–28) 27.8 (25.6–32) 12 (8.6–18.1)

m, month; AA, artesunate-amodiaquine; AL, artemether-lumefantrine; DHP, dihydroartemisinin-piperaquine; PCT, parasite clearance time; HCT, haematocrit; CI, confidence interval; PEAA, persistent early-appearing anaemia; LAA, late-appearing anaemia.

a

Geometric mean.

b

No significant difference between nadir haematocrit during PEAA and LAA (p = 0.08).

c

Virtually all patients were asymptomatic during PEAA and LAA.

d

Time from commencement of treatment to occurrence of LAA.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.